Commitments and Contingencies (Details) - USD ($)			1 Months Ended		6 Months Ended
	Sep. 13, 2021	Mar. 03, 2021	Mar. 27, 2015	Nov. 20, 2014	Jun. 30, 2022	Mar. 10, 2022	Feb. 16, 2022	Dec. 31, 2021	Jan. 29, 2021	Nov. 22, 2019	Dec. 31, 2017
Commitments and Contingencies (Details) [Line Items]
Account payable, other					$ 100,000			$ 100,000
Incentive units			50.00%
Aggregate of accrued technology services											$ 200,000
Licensing agreement, description				The Company is required to pay UM up to 3% of net sales on products or services developed from the technology. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology. Under the agreement, the Company is required to pay an annual fee to UM. On December 11, 2017, the original agreement with UM was amended. The amendment provided that for a $5,000 fee the dates of the milestone completions were amended and replaced as follows: (a) by December 31, 2021, to have completed Phase II clinical trials for the products; and (b) by September 1, 2025, to have completed Phase III clinical trials for products. In addition, one-year extensions may be granted on these milestone dates by making a payment of $5,000. Upon completion of the Phase II clinical trials, a milestone payment of $250,000 is due. Upon completion of the Phase III clinical trials, a milestone payment of $750,000 is due. As of June 30, 2022, the Company had accrued $46,667 based on the terms of the agreement. In addition, on November 14, 2014, as required by the license agreement the Company issued 20,000 series C membership units valued at $0.5 million to UM. The Company recorded this $500,000 as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years.
Legal fees		$ 100,000
Defray patent costs		70,000
Installments paid		$ 7,500
Issuance of additional unregistered shares (in Shares)		110,387
Milestone payments description					The Company and UM agreed to the following modification of the milestone payments: (a) No payment will be due upon the completion of Phase 2 clinical trials for the product; (b) a one-time payment of $0.5 million, payable within six months of the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (c) a one-time payment of $0.5 million payable within six months of the receipt by the Company of approval for the first new drug application (“NDA”), biologics application (“BLA”), or other marketing or licensing application for the product; and (d) a one-time payment of $0.5 million payable within six months of the first sale following product approval.
Litigation amount	$ 1,400,000
Series C Units [Member]
Commitments and Contingencies (Details) [Line Items]
Shares issued (in Shares)									410	820	1,901
Class A Common Stock [Member]
Commitments and Contingencies (Details) [Line Items]
Converted shares (in Shares)					16,755
Master Services Agreements [Member]
Commitments and Contingencies (Details) [Line Items]
Expenditure amount					$ 3,400,000
Account payable, other						$ 1,000,000
Consulting Services Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Company expense				$ 265,000
Accrued balance					$ 200,000			$ 200,000
CD271 [Member]
Commitments and Contingencies (Details) [Line Items]
Agreement description					The Company is required to pay as royalty, 1% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $250,000 to JMHMD, and issued to it 10,000 Series C Units, valued at $250,000. The $0.5 million of value provided to JMHMD for the license agreement, along with professional fees of approximately $27,000, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over 20 years.
Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Advance amount							$ 10,000